Work

Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?

Year: 2023

Type: article

Abstract: Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies. See related article by Jain et al., p. 498.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-23-2872

Authors: Othman Al-Sawaf, Matthew S. Davids

Institutions: University of Cologne, The Francis Crick Institute, University Hospital Cologne, University College London, Dana-Farber Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Deutsche Forschungsgemeinschaft, National Institutes of Health, National Cancer Institute